Beacon is investigating the gene therapy in other pivotal trials, including the VISTA trial that is expected to readout in H2 2026.

Gene Therapeutics has reported additional interim outcomes from its ongoing LEGEND Phase II trial assessing detalimogene voraplasmid for BCG-unresponsive NMIBC.

ENTR-601-44 didn’t elevate dystrophin levels to analyst expectations, or to the baseline change recorded by Novartis’ del-zota.

MEDSIR has reported data from the PHERGain and PHERGain-2 trials, which focused on targeted therapies in early HER2-positive breast cancer.